Caris Life Sciences delivered exceptional third-quarter results, with revenues soaring 113% year-over-year to $216.8 million, reflecting strong demand in molecular profiling services and significant margin improvements.

• Molecular profiling services revenues shot up 121% year-over-year to $207.6 million, supported by a robust increase in clinical case volumes and average selling prices (ASP).
• Clinical case volumes reached nearly 51,000, marking 18.2% growth, while ASP rose to $4,089 per profile, up 87% year-over-year, driven by changes in reimbursement rates.
• Gross margins improved dramatically to 68% from 43.7% in Q3 2024, aided by operational efficiencies and strong revenue growth.
• Positive adjusted EBITDA of $51.2 million and net income of $24.3 million underscore a significant milestone in profitability.
• Cash on hand increased to nearly $760 million, providing strategic flexibility for future investments in technology and early detection markets.